A fully funded P3 in progress.
Significantly back ended deal.
'Low bar' end points when taking P2 results into account.
ROW rights still up for grabs.
A reputedly superior 'baby brother' drug in the background, now funded through P2 trials for 3 rare diseases.
Realistic chance that the tech could cover the autism spectrum.
IS THIS A DREAM INVESTMENT?
For me, the answer is a big fat NO. Why?
Because the market cap has been destroyed and the register set up to profit an invading cancer intent on a low ball takeover.
A total failure of management.
Ann: Completion of Share Purchase Plan, page-15
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.15 |
Change
0.100(0.77%) |
Mkt cap ! $1.680B | |||
| Open | High | Low | Value | Volume |
| $13.14 | $13.44 | $13.04 | $3.493M | 264.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1446 | $13.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.21 | 395 | 1 |
View Market Depth
| Last trade - 16.10pm 13/02/2025 (20 minute delay) ? |
| NEU (ASX) Chart |